New SYNC-T therapy shows promise for tough prostate cancer
Disease control
Recruiting now
This study tests a new treatment called SYNC-T therapy (SV-102) in 70 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to find the safest and most effective dose and to see if the treatment can …
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated May 06, 2026 16:03 UTC